» Articles » PMID: 36473552

Viral Cultures, Cycle Threshold Values and Viral Load Estimation for Assessing SARS-CoV-2 Infectiousness in Haematopoietic Stem Cell and Solid Organ Transplant Patients: a Systematic Review

Overview
Journal J Hosp Infect
Date 2022 Dec 6
PMID 36473552
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Solid organ and haematopoietic stem cell transplant recipients are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) than non-transplant recipients due to immunosuppression, and may pose a continued transmission risk, especially within hospital settings. Detailed case reports including symptoms, viral load and infectiousness, defined by the presence of replication-competent viruses in culture, provide an opportunity to examine the relationship between clinical course, burden and contagiousness, and provide guidance on release from isolation.

Objectives: To investigate the relationship between serial SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) cycle threshold (Ct) value or cycle of quantification value, or other measures of viral burden and the likelihood and duration of the presence of infectious virus based on viral culture, including the influence of age, sex, underlying pathologies, degree of immunosuppression, and/or vaccination on this relationship, in transplant recipients.

Methods: LitCovid, medRxiv, Google Scholar and the World Health Organization COVID-19 database were searched from 1 November 2019 to 26 October 2022. Studies reporting relevant data (results from serial RT-PCR testing and viral culture data from the same respiratory samples) for transplant recipients with SARS-CoV-2 infection were included in this systematic review: Methodological quality was assessed using five criteria, and the data were synthesized narratively and graphically.

Results: Thirteen case reports and case series reporting on 41 transplant recipients (22 renal, five cardiac, one bone marrow, two liver, one bilateral lung and 10 blood stem cell) were included in this review. A relationship was observed between proxies of viral burden and likelihood of shedding replication-competent SARS-CoV-2. Three individuals shed replication-competent viruses for >100 days after symptom onset. Lack of standardization of testing and reporting platforms precludes establishing a definitive viral burden cut-off. However, the majority of transplant recipients stopped shedding replication-competent viruses when the Ct value was >30 despite differences across platforms.

Conclusions: Viral burden is a reasonable proxy for infectivity when considered within the context of the clinical status of each patient. Standardized study design and reporting are essential to standardize guidance based on an increasing evidence base.

Citing Articles

Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics.

Savolainen L, Peltola J, Hilla R, Aman T, Broas M, Junttila I Microbiol Spectr. 2024; 13(1):e0163024.

PMID: 39589150 PMC: 11705943. DOI: 10.1128/spectrum.01630-24.


Oro-faecal transmission of SARS-CoV-2: A systematic review of studies employing viral culture from gastrointestinal and other potential oro-faecal sources and evidence for transmission to humans.

Gandini S, Conly J, Spencer E, Evans D, Rosca E, Brassey J Epidemiol Infect. 2024; 152:e138.

PMID: 39529596 PMC: 11574600. DOI: 10.1017/S0950268824001481.


Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.

Chung Y, Lam C, Tan P, Tsang H, Wong S Int J Mol Sci. 2024; 25(15).

PMID: 39125722 PMC: 11312261. DOI: 10.3390/ijms25158155.


Analysis of two sequential SARS-CoV-2 outbreaks on a haematology-oncology ward and the role of infection prevention.

van der Zwet W, Klomp-Berens E, Demandt A, Dingemans J, van der Veer B, van Alphen L Infect Prev Pract. 2024; 6(1):100335.

PMID: 38292209 PMC: 10826166. DOI: 10.1016/j.infpip.2023.100335.


Early combination therapy of COVID-19 in high-risk patients.

Orth H, Flasshove C, Berger M, Hattenhauer T, Biederbick K, Mispelbaum R Infection. 2023; 52(3):877-889.

PMID: 38017344 PMC: 11142969. DOI: 10.1007/s15010-023-02125-5.


References
1.
Alshukairi A, Tolah A, Dada A, Al-Tawfiq J, Almagharbi R, Saeedi M . Test-based de-isolation in COVID-19 immunocompromised patients: Cycle threshold value versus SARS-CoV-2 viral culture. Int J Infect Dis. 2021; 108:112-115. PMC: 8123529. DOI: 10.1016/j.ijid.2021.05.027. View

2.
Han A, Rodriguez T, Beck E, Relich R, Udeoji D, Petrak R . Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients. Curr Probl Cancer Case Rep. 2021; 3:100057. PMC: 7834336. DOI: 10.1016/j.cpccr.2021.100057. View

3.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

4.
Tarhini H, Recoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P . Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. J Infect Dis. 2021; 223(9):1522-1527. PMC: 7928754. DOI: 10.1093/infdis/jiab075. View

5.
Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View